These 6 companies are using AI to streamline clinical trials for pharma

Taking stock of the drug industry, from the lab to the medicine chest

November 14, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster The drug, from Shanghai-based LaNova Medicines, targets PD-1 and VEGF, an approach a number of experimental drugs are taking. By Matthew Herper and Adam Feuerstein STAT+ | FDA is still struggling with a lack of inspectors, but doesn't have a plan, watchdog finds A key reason positions haven't been filled is that they require travel that ranges from 25% to 75% of the time. By Ed Silverman STAT+ | Vertex's upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain The sciatica study results, expected shortly, will be crucial for Vertex, and for people wracked by chronic pain By Jonathan Wosen Adobe STAT+ | Neurogene and the race to the bottom of gene therapy Companies developing genetic medicines for even the rarest and most severe diseases should be conducting randomized, placebo-controlled clinical trials. By Adam Feuerstein STAT+ | Mild Alzheimer's patients won't save Cassava Sciences A nominal win with a narrower population will not be enough for the drug to secure FDA approval for the therapy, called simufilam. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser